loader

Aligos Therapeutics Inc.

NASDAQ:ALGS
1 min read

Aligos Therapeutics to Present at Upcoming Investor Conferences

Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025

Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184

Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference

Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025

Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting

Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

Latest News

More News

Latest News

Outlook Reports world

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES